Anna FÃ¤rnert

List of Publications by Year
in descending order

88 papers	4,756 citations	126907 33 h-index	114465 63 g-index

95 all docs	95 docs citations	95 times ranked	9328 citing authors

#	Article	IF	Citations
1	Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. Clinical Infectious Diseases, 2022, 74, 1199-1207.	5.8	7
2	Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data. Thorax, 2022, 77, 1-10.	5.6	24
3	Distinct kinetics of antibodies to 111 Plasmodium falciparum proteins identifies markers of recent malaria exposure. Nature Communications, 2022, 13, 331.	12.8	10
4	The accuracy of fully automated algorithms for surveillance of healthcare-onset Clostridioides difficile infections in hospitalized patients. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	0
5	SARS-CoV-2 testing in patients with low COVID-19 suspicion at admission to a tertiary care hospital, Stockholm, Sweden, March to September 2020. Eurosurveillance, 2022, 27, .	7.0	2
6	Erythrocytes Induce Vascular Dysfunction in COVID-19. JACC Basic To Translational Science, 2022, 7, 193-204.	4.1	26
7	Plasmodium falciparum-Specific Memory B-Cell and Antibody Responses Are Associated With Immunity in Children Living in an Endemic Area of Kenya. Frontiers in Immunology, 2022, 13, 799306.	4.8	3
8	Systems analysis shows a role of cytophilic antibodies in shaping innate tolerance to malaria. Cell Reports, 2022, 39, 110709.	6.4	10
9	Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. Journal of Clinical Investigation, 2021, 131, .	8.2	88
10	Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses. BMC Infectious Diseases, 2021, 21, 494.	2.9	16
11	Enhanced virulence of Plasmodium falciparum in blood of diabetic patients. PLoS ONE, 2021, 16, e0249666.	2.5	7
12	Biomarkers of cellular aging during a controlled human malaria infection. Scientific Reports, 2021, 11, 18733.	3.3	4
13	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight, 2021, 6, .	5.0	27
14	Multiplicity of Asymptomatic Plasmodium falciparum Infections and Risk of Clinical Malaria: A Systematic Review and Pooled Analysis of Individual Participant Data. Journal of Infectious Diseases, 2020, 221, 775-785.	4.0	24
15	Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot. Journal of Immunological Methods, 2020, 478, 112715.	1.4	14
16	Malaria and risk of lymphoid neoplasms and other cancer: a nationwide population-based cohort study. BMC Medicine, 2020, 18, 296.	5.5	7
17	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	28.9	1,561
18	Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season. Nature Medicine, 2020, 26, 1929-1940.	30.7	91

#	Article	IF	Citations
19	Stabilization of blood for long-term storage can affect antibody-based recognition of cell surface markers. Journal of Immunological Methods, 2020, 481-482, 112792.	1.4	1
20	Effectiveness of Sulfadoxineâ€“Pyrimethamine for Intermittent Preventive Treatment of Malaria and Adverse Birth Outcomes in Pregnant Women. Pathogens, 2020, 9, 207.	2.8	14
21	Validation of automated sepsis surveillance based on the Sepsis-3 clinical criteria against physician record review in a general hospital population: observational study using electronic health records data. BMJ Quality and Safety, 2020, 29, 735-745.	3.7	36
22	Memory B-Cell Responses Against Merozoite Antigens After Acute Plasmodium falciparum Malaria, Assessed Over One Year Using a Novel Multiplexed FluoroSpot Assay. Frontiers in Immunology, 2020, 11, 619398.	4.8	6
23	A panel of recombinant proteins from human-infective Plasmodium species for serological surveillance. Malaria Journal, 2020, 19, 31.	2.3	12
24	Profiles of Plasmodium falciparum infections detected by microscopy through the first year of life in Kintampo a high transmission area of Ghana. PLoS ONE, 2020, 15, e0240814.	2.5	5
25	Persistent transmission of Plasmodium malariae and Plasmodium ovale species in an area of declining Plasmodium falciparum transmission in eastern Tanzania. PLoS Neglected Tropical Diseases, 2019, 13, e0007414.	3.0	94
26	Influenza A Virus Infection Induces Hyperresponsiveness in Human Lung Tissue-Resident and Peripheral Blood NK Cells. Frontiers in Immunology, 2019, 10, 1116.	4.8	51
27	Urothelial cell senescence is not linked with telomere shortening. Journal of Tissue Engineering and Regenerative Medicine, 2019, 13, 1518-1527.	2.7	1
28	Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure. BMC Medicine, 2019, 17, 22.	5.5	47
29	Pregnancy andCYP3A5Genotype Affect Day 7 Plasma Lumefantrine Concentrations. Drug Metabolism and Disposition, 2019, 47, 1415-1424.	3.3	13
30	B cell profiling in malaria reveals expansion and remodeling of CD11c+ B cell subsets. JCI Insight, 2019, 4, .	5.0	48
31	Malaria in Eritrean migrants newly arrived in seven European countries, 2011 to 2016. Eurosurveillance, 2019, 24, .	7.0	9
32	Flt3 ligand expands bona fide innate lymphoid cell precursors in vivo. Scientific Reports, 2018, 8, 154.	3.3	12
33	Cellular aging dynamics after acute malaria infection: A 12â€month longitudinal study. Aging Cell, 2018, 17, e12702.	6.7	38
34	Cutaneous, mucocutaneous and visceral leishmaniasis in Sweden from 1996â€“2016: a retrospective study of clinical characteristics, treatments and outcomes. BMC Infectious Diseases, 2018, 18, 632.	2.9	14
35	KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. Frontiers in Immunology, 2018, 9, 2866.	4.8	26
36	Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An Observational Study. EBioMedicine, 2018, 36, 131-139.	6.1	43

#	Article	IF	Citations
37	The Malaria-Protective Human Glycophorin Structural Variant DUP4 Shows Somatic Mosaicism and Association with Hemoglobin Levels. American Journal of Human Genetics, 2018, 103, 769-776.	6.2	21
38	Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. International Journal for Parasitology, 2017, 47, 153-162.	3.1	19
39	Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study. Clinical Infectious Diseases, 2017, 65, 949-958.	5.8	44
40	Oilâ€Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 457-465.	2.5	5
41	Detection of Malaria Parasites After Treatment in Travelers: A 12-months Longitudinal Study and Statistical Modelling Analysis. EBioMedicine, 2017, 25, 66-72.	6.1	53
42	Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection. Clinical Infectious Diseases, 2017, 64, 645-653.	5.8	65
43	High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for UncomplicatedPlasmodium falciparumMalaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clinical Infectious Diseases, 2017, 64, 199-206.	5.8	41
44	Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. PLoS ONE, 2017, 12, e0188754.	2.5	41
45	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malaria Journal, 2017, 16, 267.	2.3	28
46	Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria. Malaria Journal, 2017, 16, 303.	2.3	29
47	An antigen-specific, four-color, B-cell FluoroSpot assay utilizing tagged antigens for detection. Journal of Immunological Methods, 2016, 433, 23-30.	1.4	21
48	Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children. Infection and Immunity, 2016, 84, 950-963.	2.2	45
49	Parallel telomere shortening in multiple body tissues owing to malaria infection. Proceedings of the Royal Society B: Biological Sciences, 2016, 283, 20161184.	2.6	52
50	Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity. Scientific Reports, 2016, 6, 19472.	3.3	52
51	Asymptomatic MulticlonalPlasmodium falciparumInfections Carried Through the Dry Season Predict Protection Against Subsequent Clinical Malaria. Journal of Infectious Diseases, 2015, 212, 608-616.	4.0	48
52	Imported malaria in pregnant women: A retrospective pooled analysis. Travel Medicine and Infectious Disease, 2015, 13, 300-310.	3.0	23
53	Simple Real-Time PCR and Amplicon Sequencing Method for Identification of Plasmodium Species in Human Whole Blood. Journal of Clinical Microbiology, 2015, 53, 2251-2257.	3.9	25
54	Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity. BMC Medicine, 2015, 13, 114.	5.5	27

#	Article	IF	Citations
55	Understanding the Relationship BetweenPlasmodium falciparumGrowth Rate and Multiplicity of Infection. Journal of Infectious Diseases, 2015, 211, 1121-1127.	4.0	25
56	Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. PLoS Neglected Tropical Diseases, 2015, 9, e0004068.	3.0	19
57	Epidemiology of malaria in a village in the Rufiji River Delta, Tanzania: declining transmission over 25Âyears revealed by different parasitological metrics. Malaria Journal, 2014, 13, 459.	2.3	22
58	African origin of the malaria parasite Plasmodium vivax. Nature Communications, 2014, 5, 3346.	12.8	167
59	Breadth of Anti-Merozoite Antibody Responses Is Associated With the Genetic Diversity of Asymptomatic Plasmodium falciparum Infections and Protection Against Clinical Malaria. Clinical Infectious Diseases, 2013, 57, 1409-1416.	5.8	61
60	Genetic diversity of Plasmodium falciparum infections in mild and severe malaria of children from Kampala, Uganda. Parasitology Research, 2013, 112, 1691-1700.	1.6	56
61	Longâ€lived <scp>P</scp>lasmodium falciparum specific memory <scp>B</scp> cells in naturally exposed <scp>S</scp>wedish travelers. European Journal of Immunology, 2013, 43, 2919-2929.	2.9	61
62	Plasmodium falciparum Infection Patterns Since Birth and Risk of Severe Malaria: A Nested Case-Control Study in Children on the Coast of Kenya. PLoS ONE, 2013, 8, e56032.	2.5	8
63	Plasmodium falciparum Line-Dependent Association of In Vitro Growth-Inhibitory Activity and Risk of Malaria. Infection and Immunity, 2012, 80, 1900-1908.	2.2	14
64	Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5. Vaccine, 2012, 30, 1583-1593.	3.8	28
65	Artemetherâ€“lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania. Malaria Journal, 2012, 11, 176.	2.3	26
66	High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria. PLoS ONE, 2012, 7, e32242.	2.5	49
67	Clearance of Asymptomatic P. falciparum Infections Interacts with the Number of Clones to Predict the Risk of Subsequent Malaria in Kenyan Children. PLoS ONE, 2011, 6, e16940.	2.5	21
68	Influences of Intermittent Preventive Treatment and Persistent Multiclonal Plasmodium falciparum Infections on Clinical Malaria Risk. PLoS ONE, 2010, 5, e13649.	2.5	15
69	Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine during Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania. Antimicrobial Agents and Chemotherapy, 2010, 54, 4780-4788.	3.2	48
70	Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya. PLoS Medicine, 2010, 7, e1000304.	8.4	221
71	Transmissionâ€Dependent Tolerance to MulticlonalPlasmodium falciparumInfection. Journal of Infectious Diseases, 2009, 200, 1166-1175.	4.0	36
72	Genetics of susceptibility to malaria related phenotypes. Infection, Genetics and Evolution, 2009, 9, 97-103.	2.3	14

#	Article	IF	Citations
73	Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malaria Journal, 2009, 8, 78.	2.3	73
74	Plasmodium falciparum population dynamics: only snapshots in time?. Trends in Parasitology, 2008, 24, 340-344.	3.3	34
75	Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles. Malaria Journal, 2008, 7, 241.	2.3	34
76	Influence of Consecutiveâ€Day Blood Sampling on Polymerase Chain Reactionâ€“Adjusted Parasitological Cure Rates in an Antimalarialâ€Drug Trial Conducted in Tanzania. Journal of Infectious Diseases, 2007, 195, 597-601.	4.0	42
77	Immunogenetic Control of Antibody Responsiveness in a Malaria Endemic Area. Human Immunology, 2007, 68, 165-169.	2.4	24
78	Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes and Infection, 2007, 9, 103-110.	1.9	66
79	HIGH FREQUENCY OF RECOMBINATION-DRIVEN ALLELIC DIVERSITY AND TEMPORAL VARIATION OF PLASMODIUM FALCIPARUM MSP1 IN TANZANIA. American Journal of Tropical Medicine and Hygiene, 2007, 76, 1037-1045.	1.4	23
80	High frequency of recombination-driven allelic diversity and temporal variation of Plasmodium falciparum msp1 in Tanzania. American Journal of Tropical Medicine and Hygiene, 2007, 76, 1037-45.	1.4	12
81	LIMITED ADVANTAGE OF MULTIPLE CONSECUTIVE SAMPLES FOR GENOTYPING PLASMODIUM FALCIPARUM POPULATIONS DURING THE FIRST DAYS OF TREATMENT. American Journal of Tropical Medicine and Hygiene, 2005, 73, 204-206.	1.4	13
82	Limited advantage of multiple consecutive samples for genotyping Plasmodium falciparum populations during the first days of treatment. American Journal of Tropical Medicine and Hygiene, 2005, 73, 204-6.	1.4	4
83	Elevated anti-malarial IgE in asymptomatic individuals is associated with reduced risk for subsequent clinical malaria. International Journal for Parasitology, 2004, 34, 935-942.	3.1	63
84	Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ: British Medical Journal, 2003, 326, 628-629.	2.3	71
85	In vitro recombination during PCR of Plasmodium falciparum DNA: a potential pitfall in molecular population genetic analysis. Molecular and Biochemical Parasitology, 2002, 122, 211-216.	1.1	33
86	Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis.. American Journal of Tropical Medicine and Hygiene, 2002, 66, 487-491.	1.4	28
87	Complexity ofPlasmodium falciparumInfections Is Consistent over Time and Protects against Clinical Disease in Tanzanian Children. Journal of Infectious Diseases, 1999, 179, 989-995.	4.0	115
88	Daily Dynamics of Plasmodium falciparum Subpopulations in Asymptomatic Children in a Holoendemic Area. American Journal of Tropical Medicine and Hygiene, 1997, 56, 538-547.	1.4	189